

Certificate of Analysis

MLCK, active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-638, 14-638-K, 14-638M

Parent Lot # 1611522

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal 6His. tagged, recombinant, human MLCK, amino acids 1425–1771, expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA agarose. Purity 88.9% by SDS-PAGE and Coomassie blue staining. MW = 43.7kDa.

Specific Activity (Parent lot# 1611522): 224U/mg, where one unit of MLCK, active activity is defined as 1nmol phosphate incorporated into 250μM (KKLNRTLSFAEPG) per minute at 30°C with a final ATP concentration of 100μM.

Formulation: 1.76mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 19.2–53ng of this lot of enzyme phosphorylated 250μM (KKLNRTLSFAEPG) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as MLCK with the translated native sequence listed on page three.



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
2. **(KKLNRTLSFAEPG):** Use at a final concentration of 250µM. Make a 2.5mM stock. Use 2.5µl of stock solution per assay point.
3. **MLCK, active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 19.2–53ng per assay point.
4. **[γ -³³P]ATP:** 2.5 x magnesium acetate/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)
5. **CaCl₂:** Use at a final concentration of 0.5mM. Make a 5mM stock. Use 2.5µl of stock solution per assay point.
6. **Calmodulin:** Use at a final assay concentration of 1µM. Make a 0.3mg/ml stock solution. Use 1.33µl of stock per assay point.

Assay Procedure (96 well plate format):

1. Add 5µl of 5 x reaction buffer per assay to wells.
2. Add 2.5µl of **(KKLNRTLSFAEPG)**.
3. Add **2.5µl (19.2–53ng) MLCK, active**.
4. Add 2.5µl of 5mM CaCl₂.
5. Add 1.33µl of 0.3mg/ml calmodulin.
6. Add 1.17µl of dH₂O.
7. Add 10µl of diluted [γ -³³P]ATP mixture.
8. Incubate for 10 minutes at 30°C.
9. Stop the reaction by adding 5µl of 3% phosphoric acid.
10. Transfer a 10µl aliquot onto the appropriate area of a **P30 Filtermat**.
11. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
12. Wash the filtermat once for 2 minutes with methanol.
13. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
14. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

Certificate of Analysis

MLCK Sequence Information

<u>Protein</u>	Human MLCK
<u>Tags</u>	N-terminal 6His
<u>Native sequence</u>	G31 of the recombinant protein is equivalent to G1425 of human MLCK
<u>Accession number</u>	GenBank NM_053025

Recombinant MLCK amino acid sequence:

```

1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF GEKPEEPKDE VEVSDDDKE PEVDYRTVTI
61 NTEQKVSDFY DIEERLGSGK FGQVFRLEK KTRKVVAGKF FKAYSKEKE NIRQEISIMN
121 CLHHPKLVQC VDAFEKANI VMVLEIVSGG ELFERIIDE FELTERECIK YMRQISEGVE
181 YIHKQGIVHL DLKPENIMCV NKTGTRIKLI DFGLARRLEN AGSLKVLFGT PEFVAPEVIN
241 YEPIGYATDM WSIGVICYIL VSGLSPFMGD NDNETLANVT SATWDFDDEA FDEISDDAKD
301 FISNLLKKDM KNRLDCTQCL QHPWLMKDTK NMEAKKLSKD RMKKYMARRK WQKTGNVRA
361 IGRLLSSMAMI SGLSGRK

```

Recombinant MLCK nucleotide sequence:

```

1 atgtcgtact accatcacca tcaccatcac gattacgata tcccaacgac cgaaaacctg
61 tattttcagg gcgcatgga tccggaattc ggagagaaac ctgaagagcc gaaggatgaa
121 gtggagggtg cagatgatga tgagaaggag cccgagggtg attaccggac agtgacaatc
181 aatactgaac aaaaagtatc tgacttctac gacattgagg agagattagg atctgggaaa
241 tttggacagg tctttcgact tgtagaaaag aaaactcgaa aagtctgggc agggaaagtc
301 ttcaaggcat attcagcaaa agagaaagag aatatccggc aggagattag catcatgaac
361 tgctccacc accctaagct ggtccagtgt gtggatgcct ttgaagaaaa ggccaacatc
421 gtcatggtcc tggagatcgt gtcaggaggg gagctgtttg agcgcacatc tgacgaggac
481 tttgagctga cggagcgtga gtgcatcaag tacatgcggc agatctcggg gggagtggag
541 tacatccaca agcaggggat cgtgcacctg gacctcaagc cggagaacat catgtgtgtc
601 aacaagacgg gcaccaggat caagctcatc gactttggtc tggccaggag gctggagaac
661 gcgggggtctc tgaaggtcct ctttggcacc ccagaatttg tggctcctga agtgatcaac
721 tatgagccca tcggctacgc cacagacatg tggagcatcg gggcatctg ctacatccta
781 gtcagtggcc tttccccctt catgggagac aacgataacg aaaccttggc caacgttacc
841 tcagccacct gggacttcga cgacgaggca ttcgatgaga tctccgacga tgccaaggat
901 ttcatcagca atctgctgaa gaaagatatg aaaaaccgcc tggactgcac gcagtgcctt
961 cagcatccat ggctaataa agataccaag aacatggagg ccaagaaact ctccaaggac
1021 cggatgaaga agtacatggc aagaaggaaa tggcagaaaa cgggcaatgc tgtgagagcc
1081 attggaagac tgtcctctat ggcaatgatc tcagggtca gtggcaggaa ataa

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.